Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Biotech ETFs offer investors exposure to the most innovative and growth-oriented industry within the traditionally defensive ...

REPAIRome specifically addresses the repair of one of the most serious types of DNA damage, DNA double-strand breaks (DSBs).

Katy Rezvani, MD, PhD, discusses advancements in CAR-NK cell therapy, focusing on enhancing antitumor efficacy while ensuring safety through precise gene editing techniques.

Today, Benzinga's options scanner spotted 14 options trades for CRISPR Therapeutics. This is not a typical pattern. The sentiment among these major traders is split, with 28% bullish and 42% bearish.

The entire rationale behind this multi-pronged screening was the discovery of checkpoints or regulators that are critically involved in inducing suppression in NK cells under these diverse negative ...

A gene-editing therapy led to durable changes in serum transthyretin levels among people with hereditary transthyretin ...

CRISPR Therapeutics has developed SyNTase editing, a proprietary, next-generation, site-specific gene correction platform.

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the Unstoppable Stocks to Buy and Hold for the Next 5 Years. On September 23, ...

Stunning success in halting Huntington's disease with gene therapy offers new hope to those with the disorder—and potential ...

Becoming a millionaire through stock investing is possible, but it requires patience, discipline, and the acumen to make informed investment choices. Not every company can generate the kind of returns ...